This study provides new clinical evidence for immunotherapy strategies in mCRPC, suggesting that dual immune checkpoint blockade targeting CTLA-4 and PD-1 has antitumor activity in selected patients, offering guidance for subsequent biomarker-driven personalized treatment design.
Literature Overview
The article 'Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial', published in Nature Communications, systematically investigates the efficacy and safety of nivolumab combined with ipilimumab in patients with chemotherapy-refractory metastatic castration-resistant prostate cancer (mCRPC). Using a multi-cohort design, the study compares clinical outcomes of different immunotherapy regimens versus standard second-line chemotherapy (cabazitaxel), and integrates spatial proteomics to explore potential predictive biomarkers. The results not only validate objective responses to dual immunotherapy in a subset of mCRPC patients but also propose a novel transcriptional signature based on tumor microenvironment architecture that may help identify patients most likely to benefit.Background Knowledge
Metastatic castration-resistant prostate cancer (mCRPC) is a highly heterogeneous and treatment-resistant advanced disease. Despite available therapies such as androgen receptor pathway inhibitors (e.g., enzalutamide, abiraterone) and chemotherapy (e.g., docetaxel, cabazitaxel), most patients eventually progress. Currently, immune checkpoint inhibitors show limited efficacy in mCRPC, with responses observed only in specific molecular subtypes such as those with high tumor mutational burden (TMB) or mismatch repair deficiency (dMMR), indicating that a cold tumor microenvironment and low immunogenicity are major barriers. Combination immunotherapy targeting both PD-1 and CTLA-4 has demonstrated synergistic effects in melanoma and other cancers, but a clear patient selection strategy remains lacking in mCRPC. This study focuses on optimizing the dosing regimen of nivolumab and ipilimumab to improve tolerability and leverages spatial multi-omics analysis to uncover tumor microenvironment features associated with response—particularly the spatial co-localization structures among CD8+ T cells, CD4+ T cells, CD14+ myeloid cells, and CD31+ vascular endothelial cells—aiming to establish a predictive immune niche model.
Research Methods and Experiments
The study is based on the randomized portion of the phase 2, open-label, multi-cohort CheckMate 650 trial, enrolling 259 men with mCRPC who had previously received docetaxel. Patients were randomized in a 2:2:1:2 ratio across four cohorts: nivolumab 3mg/kg + ipilimumab 1mg/kg Q3W×4 (N3I1, n=73), nivolumab 1mg/kg Q3W×8 + ipilimumab 3mg/kg Q6W×4 (N1I3, n=74), ipilimumab monotherapy 3mg/kg Q3W×4 (I-mono, n=38), or cabazitaxel chemotherapy (CABA, n=74). Primary endpoints were objective response rate (ORR) and radiographic progression-free survival (rPFS); secondary endpoints included overall survival (OS), PSA response rate, and safety. The study was not designed for statistical comparisons between cohorts but provides reference for efficacy trends. To explore biomarkers, baseline tumor tissues were analyzed using CODEX multiplex immunofluorescence for spatial proteomics, focusing on perivascular immune cell aggregates marked by CD31+, and the prognostic value of identified structures was validated using the TCGA database.Key Conclusions and Perspectives
Research Significance and Prospects
This study further confirms the antitumor activity of combined PD-1 and CTLA-4 blockade in a subset of mCRPC patients, particularly observing a higher ORR with the N1I3 regimen, suggesting that optimized dosing schedules can enhance efficacy. More importantly, it introduces a novel biomarker based on spatial tissue architecture, going beyond traditional markers such as TMB or PD-L1 expression, potentially offering a more accurate reflection of functional antitumor immune states. This finding has profound implications for drug development, supporting future prospective trials in mCRPC based on immune microenvironment subtyping. Additionally, the validation of this niche feature offers new avenues for clinical monitoring, such as tracking dynamic cell interactions via digital pathology or liquid biopsy. Moreover, these mechanistic insights provide a theoretical foundation for building disease modeling systems—such as organoid co-culture models—that more closely mimic clinical responses, advancing the development of personalized immunotherapy strategies.
Conclusion
This study provides critical clinical evidence for immunotherapy in metastatic castration-resistant prostate cancer (mCRPC), demonstrating that nivolumab combined with ipilimumab can induce deep and durable tumor responses in a subset of patients, with an objective response rate approaching 20% under the N1I3 dosing regimen. Although overall rPFS did not surpass that of cabazitaxel, the study leveraged innovative spatial proteomic analysis to identify a “perivascular immune niche” composed of CD14+ myeloid cells, CD8+ T cells, and CD31+ vascular endothelial cells, whose density significantly correlates with patient overall survival. This finding not only reveals a potential mechanism of response but also provides a quantifiable histological marker for future precision screening of patients likely to benefit from immunotherapy. From a translational perspective, the study underscores the importance of spatial architecture within the tumor microenvironment, suggesting that conventional molecular markers such as TMB may be insufficient for predicting immunotherapy outcomes. Therefore, integrating spatial multi-omics data will help build more accurate predictive models and advance strategies to convert “cold” tumors into “hot” ones in mCRPC. Ultimately, this work lays the foundation for improving patient care in mCRPC, marking a milestone in the design of personalized immunotherapy pathways.
